Outlook Therapeutics, Inc.
NASDAQ:OTLKBiotechnology
-$0.10 today
- Market cap
- $99.30M
- Beta
- 0.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.74
Volume 4.42M
Average 17.46M
OTLK Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Outlook Therapeutics, Inc.NASDAQ: OTLK
Other Non-Cash Items · Q2 FY2026 · quarter ended Mar 2026
Other non-cash items turns negative
Q2 FY2026 other non-cash items was -$9.57M, compared with $33.94M a year earlier. Trailing-twelve-month other non-cash items was $7.21T. Over 3 fiscal years it compounded at +7849.1% a year.
Context
- Other non-cash items amounted to 111810612.5% of revenue in FY2025.
- Other non-cash items increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other non-cash items holds near -$9.57M or moves back toward the trailing-twelve-month quarterly average of $1.8T.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 1.58T USD
- Year-over-year change
- +38626326.8%
- 4-year CAGR
- +4538.0%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 1.58T | +38626326.8% |
| FY2024 | 2024-09-30 | 4.09M | -27.8% |
| FY2023 | 2023-09-30 | 5.66M | +80.0% |
| FY2022 | 2022-09-30 | 3.15M | +821.3% |
| FY2021 | 2021-09-30 | 341.55K | — |
Other Non-Cash Items vs competitors
How OTLK compares with its peers on the latest reported figures
- OTLK's LTM Mar 2026 other non-cash items of $7.21T is the largest of the 9 companies compared; the peer median is $2.65M.
- Its year-over-year change of +7439461.7% is the highest of 9, against a peer median of +23.1%.
- Other non-cash items amounts to 2163586741.1% of revenue for OTLK, versus a peer median of 108.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.21T | +7439461.7% | +7849.1% | 2163586741.1% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | $24.1B | +2791176.7% | +1768.5% | — |
| LTM Mar 2026 | $7.27M | -28.0% | — | 317.0% | |
| LTM Mar 2026 | $4.02M | +4090.6% | — | — | |
| LTM Mar 2026 | $2.91M | +51.9% | -58.7% | 206.0% | |
| LTM Jun 2026 | $2.4M | -5.7% | -26.7% | 11.4% | |
| LTM Mar 2026 | $2.1M | +2769.9% | — | 6.4% | |
| LTM Mar 2026 | $848K | -175.5% | -41.4% | — | |
| LTM Mar 2026 | $399K | -97.0% | — | — | |
| Peer median (excluding OTLK) | $2.65M | +23.1% | -34.0% | 108.7% | |
Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (53.16M) | (66.05M) | (58.98M) | (75.37M) | (62.42M) |
| Depreciation & Amortization | 262.14K | 204.69K | 44.19K | 113.86K | 117.05K |
| Deferred Income Tax | 498.49K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.89M | 7.71M | 5.55M | 5.39M | 8.9M |
| Change in Working Capital | (7.08M) | (1.68M) | 4.75M | (3.02M) | 4.86M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (1.49M) |
| Inventory | 0 | 0 | 0 | 0 | (3.34M) |
| Accounts Payables | (198.47K) | 1.3M | 3.08M | 1.39M | 1.67M |
| Other Working Capital | (6.88M) | (2.98M) | 1.67M | (4.41M) | 8.02M |
| Other Non-Cash Items | 341.55K | 3.15M | 5.66M | 4.09M | 1.58T |
| Operating Cash Flow | (54.25M) | (56.67M) | (42.97M) | (68.79M) | (51.83M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (3) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 6.31M | (2.32M) | 19.77M | (4.27K) | (3.04M) |
| Common Stock Issued | 46.3M | 62.31M | 30.02M | 60.33M | 48.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.59M | (394.15K) | (823.89K) | 0 | 44.98T |
| Financing Cash Flow | 56.19M | 59.59M | 48.97M | 60.33M | 44.98M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.94M | 2.92M | 6M | (8.46M) | (6.84M) |
| Free Cash Flow | (54.25M) | (56.67M) | (42.97M) | (68.79M) | (51.83M) |
Outlook Therapeutics, Inc.
NASDAQ:OTLK
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.